European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

11:07 AM EDT, 03/18/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 0.13% to 1,438.81 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies ( DBVT ) and Genfit ( GNFT ) , which rose 6.8% and 3.7% respectively. They were followed by financial services company Banco Santander (SAN) and biopharmaceutical company Cellectis ( CLLS ) , which were up 3.1% and 2.9% respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and semiconductor company Sequans Communications ( SQNS ) , which dropped 4.7% and 3.3% respectively. They were followed by internet advertising firm Criteo ( CRTO ) and pharmaceutical company Ascendis Pharma ( ASND ) , which were down 2.4% and 1.1% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics ( AKTX ) and financial services company Barclays ( JJCTF ) , which advanced 9.8% and 1.9% respectively. They were followed by financial services company HSBC ( HSBC ) and biotech firm Trinity Biotech ( TRIB ) , which increased 1% and 0.9% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Verona Pharma ( VRNA ) and Biodexa Pharmaceuticals ( BDRX ) , which fell 4.4% and 3.8% respectively. They were followed by biopharmaceutical company NuCana ( NCNA ) and biopharmaceutical company Adaptimmune Therapeutics ( ADAP ) , which lost 3.3% and 1.3% respectively.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.